

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Attorney Docket Number 5405-232DV	Serial No. 09/384,749
		Applicants: Amalfitano et al.	
		Filing Date: Concurrently herewith	Group: Unknown
<i>m</i>	63	Hardy et al.: Construction of Adenovirus Vectors through Cre-lox Recombination, <i>Journal Of Virology</i> , 71:3, 1842-1849 (1997)	
	64	Hartigan-O'Connor et al.: Increased Efficiency Of Guttled Adenovirus Production In Cells Expressing Preterminal Protein and DNA Polymerase, <i>American Society of Gene Therapy Adenoviruses</i> , Abstract #703 (1998)	
	65	Hartigan-O'Connor et al.: Improved Production of Guttled Adenovirus in Cells Expressing Adenovirus Preterminal Protein and DNA Polymerase, <i>Journal Of Virology</i> , 73:9, 7835-7841 (1999)	
	66	Hauser et al.: <i>Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy</i> , <i>Neuromuscular Disorders</i> 7, 277-283 (1997)	
	67	He et al.: A simplified system for generating recombinant adenoviruses, <i>Proc. Natl. Acad. Sci. USA</i> , 95, 2509-2514 (1998)	
	68	Hermans et al.: man lysosomal α -glucosidase: functional characterization of the cosylation sites, <i>M.J.</i> , 289, 681-686 (1993)	
	69	Hoefsloot et al.: Primary structure and processing of lysosomal α -glucosidase; homology with the intestinal sucrase - isomaltase complex, <i>The EMBO Journal</i> , 7:6, 1697-1704 (1988)	
	70	Hoefsloot et al.: Expression and routeing of human lysosomal α -glucosidase in transiently transfected mammalian cells, <i>Biochem. J.</i> , 272 485-492 (1990)	
	71	Hu et al.: Persistence of an [E1', Polymerase'] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent Mice, <i>Human Gene Therapy</i> 10, 355-364 (1999)	
	72	Ilan et al.: Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression, <i>Proc. Natl. Acad. Sci. USA</i> , 94, 2587-2592 (1997)	
	73	International Search Report; PCT/US99/19540, 1999.	
	74	Jones et al.: Isolation of Deletion and Substitution Mutants of Adenovirus Type 5, <i>Cell</i> , 13, 181-188 (1978)	
	75	Kaplan et al.: Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung, <i>Human Gene Therapy</i> , 8, 45-56 (1997)	
	76	Kochanek et al.: A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophic and β -galactosidase, <i>Proc. Natl. Acad. Sci. USA</i> , 93, 5731-5736 (1996)	
	77	Krougliak et al.: Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants, <i>Human Gene Therapy</i> , 6 1575-1586 (1995)	
	78	Kumar-Singh et al. "Encapsidated adenovirus minichromosomes as gene-delivery vehicles," <i>American Journal of Human Genetics</i> . 59:Suppl 4 page A202, ISSN: 0002-9297 (1996).	
<i>V</i>	79	Kumar-Singh et al.: Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells, <i>Human Molecular Genetics</i> 5:7, 913-921 (1996)	
	80	Kumar-Singh et al.: Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration, <i>Human Molecular Genetics</i> 7:12,	

EXAMINER
EXAMINER

DATE CONSIDERED

6/7/03

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.